Neelam Asghar, H. Mumtaz, Abdul Ahad Syed, Farea Eqbal, Reeju Maharjan, Aditya Bamboria, Manish Shrehta
{"title":"Safety, efficacy, and immunogenicity of COVID-19 vaccines; a systematic review","authors":"Neelam Asghar, H. Mumtaz, Abdul Ahad Syed, Farea Eqbal, Reeju Maharjan, Aditya Bamboria, Manish Shrehta","doi":"10.1080/25785826.2022.2068331","DOIUrl":null,"url":null,"abstract":"Abstract The World Health Organization stated on 11 March 2020 that a coronavirus illness had been discovered in Wuhan, China in December 2019. Effective vaccinations are eagerly awaited as the global outbreak of COVID-19 continues. The aim is to evaluate the safety, effectiveness, and immunogenicity of Pfizer/AstraZeneca/Modera/Cansino vaccines against COVID-19. An electronic search on different databases yielded 12,907 articles. A total of 20 randomized and non-randomized, published, and ongoing trials were selected. Cochrane RoB version 2.0 was used to assess the authenticity of the studies. Of these 20 trials, three were conducted on Pfizer, three on AstraZeneca, three on Moderna, and two on the Cansino vaccine. These trials have reported promising results for the safety, efficacy, and immunogenicity of the respective vaccines. None of the trials have reported the efficacy and severe adverse outcomes for the Cansino vaccine, hindering its reliability as a safe vaccine against covid-19. Furthermore, the results of these trials have established Pfizer to be the most efficacious vaccine against covid-19, having an efficacy of 94.6%. A few severe adverse events were reported by the included trials. However, further systematic reviews are required to understand the respective vaccine profiles on Immuno-suppressive, organ transplants, and patients with other comorbidities.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":"45 1","pages":"225 - 237"},"PeriodicalIF":2.7000,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"13","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunological Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/25785826.2022.2068331","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 13
Abstract
Abstract The World Health Organization stated on 11 March 2020 that a coronavirus illness had been discovered in Wuhan, China in December 2019. Effective vaccinations are eagerly awaited as the global outbreak of COVID-19 continues. The aim is to evaluate the safety, effectiveness, and immunogenicity of Pfizer/AstraZeneca/Modera/Cansino vaccines against COVID-19. An electronic search on different databases yielded 12,907 articles. A total of 20 randomized and non-randomized, published, and ongoing trials were selected. Cochrane RoB version 2.0 was used to assess the authenticity of the studies. Of these 20 trials, three were conducted on Pfizer, three on AstraZeneca, three on Moderna, and two on the Cansino vaccine. These trials have reported promising results for the safety, efficacy, and immunogenicity of the respective vaccines. None of the trials have reported the efficacy and severe adverse outcomes for the Cansino vaccine, hindering its reliability as a safe vaccine against covid-19. Furthermore, the results of these trials have established Pfizer to be the most efficacious vaccine against covid-19, having an efficacy of 94.6%. A few severe adverse events were reported by the included trials. However, further systematic reviews are required to understand the respective vaccine profiles on Immuno-suppressive, organ transplants, and patients with other comorbidities.
摘要世界卫生组织于2020年3月11日表示,2019年12月在中国武汉发现了一种冠状病毒疾病。随着新冠肺炎全球疫情的持续,人们热切期待有效的疫苗接种。目的是评估辉瑞/阿斯利康/莫德纳/康西诺疫苗对抗新冠肺炎的安全性、有效性和免疫原性。对不同数据库进行的电子搜索共产生12907篇文章。共选择了20项随机和非随机、已发表和正在进行的试验。Cochrane RoB 2.0版用于评估研究的真实性。在这20项试验中,三项是在辉瑞公司进行的,三项在阿斯利康公司进行的、三项在莫德纳公司进行的和两项在康西诺疫苗上进行的。这些试验报告了各自疫苗的安全性、有效性和免疫原性方面有希望的结果。没有一项试验报告了Cansino疫苗的有效性和严重不良后果,这阻碍了其作为新冠肺炎安全疫苗的可靠性。此外,这些试验的结果表明,辉瑞公司是最有效的新冠肺炎疫苗,其有效性为94.6%。纳入的试验报告了一些严重不良事件。然而,需要进一步的系统审查,以了解免疫抑制、器官移植和其他合并症患者各自的疫苗概况。